Navigation Links
Breast cancer drug shows promise for treating, preventing progestin-dependent tumors
Date:1/28/2009

COLUMBIA, Mo. Recent studies suggest that human breast cancer risk is increased by outside exposure to the hormone progestin, such as during hormone replacement therapy. Now, a University of Missouri study suggests that PRIMA-1, a small molecule drug that targets the most common mutated gene, p53, in human cancer cells, has potential as a novel chemotherapeutic treatment for progestin-accelerated human breast cancer.

"We demonstrated that PRIMA-1 was an effective drug to treat and prevent emergence of progestin-accelerated mammary tumors in rats," said Salman Hyder, professor of biomedical sciences in the College of Veterinary Medicine and the Dalton Cardiovascular Research Center. "The results of this study may have significant implications for the treatment and prevention of human breast cancer because such a large fraction of human breast cancers are dependent on estrogens and progestins for growth."

Mutated p53 plays a key role in promoting tumor cell survival and tumor cell resistance to chemotherapeutic drugs. In more than 50 percent of breast cancer cases, mutated p53 is present. Previous research has indicated that when p53 is functionally abnormal, tumor cells are prolific and develop quickly. PRIMA-1 targets and returns normal function to the mutated p53.

In the study, researchers examined the ability of PRIMA-1 to suppress growth of progestin-accelerated, mammary tumors in an animal model. When tumors reached a certain size, researchers administrated PRIMA-1 twice a day for three days. The researchers found that PRIMA-1 caused regression of approximately 40 percent of progestin-accelerated mammary tumors. However, the drug did not induce regression of native, non-progestin accelerated tumors. PRIMA-1 also suppressed the emergence of any new progestin-accelerated tumors in the animal model.

"Postmenopausal women worldwide are exposed to exogenous progestin in the form of hormone replacement therapy, and clinical studies have associated combined exposure to progestin and estrogen with an increased incidence of human breast cancer in this population," said Hyder, who is also the Zalk Endowed Professor of Tumor Angiogenesis. "Because PRIMA-1 blocked the formation of new tumors following progestin stimulation in this experimental model, it is tempting to speculate that this agent could be used to prevent progestin-accelerated tumors in women on hormone replacement therapy. However, this needs to be tested thoroughly in a clinical setting."


'/>"/>

Contact: Kelsey Jackson
JacksonKN@missouri.edu
573-882-8353
University of Missouri-Columbia
Source:Eurekalert

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. MRI finds breast cancer before it becomes dangerous
3. Pathway links inflammation, angiogenesis and breast cancer
4. Drop in breast cancer incidence linked to hormone use, not mammograms
5. Breast cancer prevention practices vary across Canada
6. Eating junk food whilst pregnant and breastfeeding may lead to obese offspring
7. Acrylamide Wont Raise Breast Cancer Risk
8. New link between estrogen and breast cancer
9. Hypnosis Eases Pain of Breast Cancer Surgery
10. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
11. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... “Crossing the ... last ten minutes of a woman’s life. “Crossing the Bar” is the creation of ... of three children. , Charlotte, who credits the inspiration of the book to ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... “Some Infallible ... of the Father. “Some Infallible Characteristics of Christ” is the creation of published author, ... of a Baptist Church for thirteen years, a preacher for over nineteen, a pastor ...
(Date:1/22/2017)... Raton, FL (PRWEB) , ... January 22, 2017 , ... ... to customers across the world, recently met with big-name retail buyers at the January ... scientific evidence of efficacy and uses the utmost safety standards in all of its ...
(Date:1/21/2017)... ... January 21, 2017 , ... Caronlab Australia, an Australian company known ... Trade Show in Hilton Head, SC, where it benefited from outstanding meetings with major ... its beauty and wellness products. At this trade show, the company had the chance ...
(Date:1/21/2017)... ... ... Seamild, the largest manufacturer of oats in China, is now aiming at ... Oat is recognized globally as one of the healthiest cereals, XieQingkui, the founder of ... a move to sow the seed of good karma. Buddhism spirit featuring benevolence and ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... Stock-Callers.com today evaluates the following Drug ... Novo Nordisk A/S (NYSE: NVO ), Sucampo Pharmaceuticals ... Inc. (NASDAQ: PTX ). These stocks belong to ... , 2017, finishing near its session lows. As per a ... while shares of health care companies in the S&P 500 ...
(Date:1/20/2017)... 2017 Avillion LLP, a co-developer and financier ... Weinberg , MD MBA as Chief Medical Officer. Dr Weinberg will ... . ... Weinberg has spent more than 17 years as a pharmaceutical and ... micro-cap biotech. Over the course of his career, he has interfaced ...
(Date:1/19/2017)... , Jan. 19, 2017 The U.S. Food ... of Chronic Idiopathic Constipation (CIC) in adult patients. ... chronic gastrointestinal disorders," said Julie Beitz , M.D., director ... Center for Drug Evaluation and Research. "With the availability of ... appropriate treatment for their condition." ...
Breaking Medicine Technology: